Article

Elasomeran (mRNA1273) Vaccine: The Journey from Preclinical Research to Clinical Trials, Authorization, and FDA Approval

2022-10-07

Abstract excerpt

<title>Abstract</title> <p>The rapid spread of COVID-19 worldwide resulted in critical illness and mortality. Supportive measures have been the center stage for therapy. One crucial question since the onset of the deadly SARS-CoV-2 pandemic was the development of a vaccine. Developed by Moderna, the mRNA1273 vaccine, Elasomeran contains a lipid nanoparticle (LNP) that encapsulates a nucleoside-modified messenger...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b8515747-3eeb-5a88-95d5-833145d307ce
DOI: 10.21203/rs.3.rs-2066957/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Elasomeran (mRNA1273) Vaccine: The Journey from Preclinical Research to Clinical Trials, Authorization, and FDA ApprovalDOI 10.21203/rs.3.rs-2066957/v1Read

An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine DevelopmentSemantic proximity Read

The Unique Features and Collateral Immune Effects of mRNA-Based COVID-19 Vaccines: Potential Plausible Causes of Adverse Events and ComplicationsSemantic proximity Read

mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious DiseasesSemantic proximity Read

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSemantic proximity Read

A Phase1 Results of a Non-Stabilized Spike-Encoding mRNA Vaccine in AdultsSemantic proximity Read

Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progressSemantic proximity Read

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2Semantic proximity Read

mRNA Vaccine Platforms and Lipid Nanoparticle Delivery Systems: Molecular Advances, Clinical Breakthroughs, and Regulatory Perspectives (2020–2025)Semantic proximity Read

Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2Semantic proximity Read

Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccinesSemantic proximity Read

Vaccines’ New Era-RNA VaccineSemantic proximity Read

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2Semantic proximity Read